Advertisement
UK markets close in 1 hour 17 minutes
  • FTSE 100

    7,648.13
    +18.11 (+0.24%)
     
  • FTSE 250

    19,195.18
    +140.31 (+0.74%)
     
  • AIM

    738.48
    +1.98 (+0.27%)
     
  • GBP/EUR

    1.1664
    -0.0018 (-0.15%)
     
  • GBP/USD

    1.2622
    -0.0004 (-0.03%)
     
  • Bitcoin GBP

    49,057.58
    -757.25 (-1.52%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,105.71
    +9.44 (+0.19%)
     
  • DOW

    38,931.93
    -64.46 (-0.17%)
     
  • CRUDE OIL

    79.66
    +1.40 (+1.79%)
     
  • GOLD FUTURES

    2,059.70
    +5.00 (+0.24%)
     
  • NIKKEI 225

    39,910.82
    +744.63 (+1.90%)
     
  • HANG SENG

    16,589.44
    +78.00 (+0.47%)
     
  • DAX

    17,699.48
    +21.29 (+0.12%)
     
  • CAC 40

    7,906.48
    -20.95 (-0.26%)
     

Vericel to Present at the Stephens Annual Investment Conference

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment Conference. The fireside chat will begin at 10:00 a.m. ET (9:00 a.m. CT) on Wednesday, November 15, 2023.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leader in advanced therapies for sports medicine and severe burn care. The Company manufactures and markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact:
Julie Downs
media@vcel.com